围绕结核性疾病的开展诊治和科研工作，研究重点方向包括结核肠道微生态、分枝杆菌病耐药机制、结核共病等方面。

1、结核病宿主免疫及耐药机制研究：围绕结核肠道微生态等开展结核宿主免疫机制研究；围绕分枝杆菌病的耐药机制开展表型、机制验证等研究。

2、疑难危重结核性疾病诊疗的应用推广：围绕重症结核、耐药结核、中枢神经系统结核、支气管结核、儿童结核等疑难危重结核性疾病开展个体化诊疗技术及体系建设，并加强推广应用；加强结核合并肿瘤、非结核分枝杆菌肺病、结核后肺疾病等早期干预及规范化诊疗水平。

1、Xie Yalin, Su Ning*,Li Chaoxia,Lei An, Li Lei, Zou Jianjun, Cen Wencang, Hu Jinxing*(通讯作者). Pulmonary blastoma treatment response to anti-PD-1 therapy: a rare case report and literature review.Frontiers in Oncology, 2023, 13: 1146204.

2、Alam MS, Guan P, Zhu Y, Zeng S, Fang X, Wang S, Yusuf B, Zhang J, Tian X, Fang C, Gao Y, Khatun MS, Liu Z, Hameed HMA, Tan Y, Hu J*, Liu J, Zhang T. Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001. Front Cell Infect Microbiol. 2023 Jan 4;12:1056007. doi: 10.3389/fcimb.2022.1056007.

3、Xie Y, Su N, Zhou W, Lei A, Li X, Li W, Huang Z, Cen W, Hu Jinxing*(通讯作者). Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor. Cancer Manag Res. 2021 Oct 1;13:7517-7526.

4、Su S, Lin A, Luo P, Zou J, Huang Z, Wang X, Zeng Y, Cen W, Zhang X, Huang H, Hu Jinxing* ( 通 讯 作 者 ), Zhang J. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Ann Transl Med. 2021 Sep;9(18):1475.

5、Tian X,Gao Y,Wang S, Hu Jinxing,et al. Rapid visualized assessment of drug efficacy in live mice with a selectable marker-free autoluminescent Klebsiella pneumoniae. [J]. Biosens Bioelectron.2021,177(3):112919.

6、Li S, Cao W, Hong W, Hu Jinxing, et al.A novel function of calcium sensing receptor in chronic hypoxia-induced pulmonary venous smooth muscle cells proliferation.[J].Hypertens Res.2020,43(4):271-280.